Skip to main content
Kane Biotech
Biofilms
Overview
Understanding Biofilms
coactiv+™
DispersinB
®
Glossary Of Terms
Commercialization Vehicles
Overview
Kane Wound Care & Surgical
Kane Dermatology
About
Overview
Our Team
Careers
Contact
Publications
Blog
Publications / Posters
News / Events
Investors
Overview
News / Events
Company Information
Financial Results
Stock Data
SEDAR
Corporate Governance
Press Releases
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
Investors
Overview
News / Events
Press Releases
IR Calendar
Email Alerts
Company Info
Profile
Overview of Kane Wound Care
DermaKB OTC Shampoo Trials
Presentations
Management Team
Contacts
Financial Results
Stock Data
TSX-V:KNE
OTCQB:KNBIF
SEDAR
Governance
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Tear Sheet
Contacts
RSS News Feed
News / Events
Press Releases
IR Calendar
Email Alerts
All News
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Kane Biotech Appoints Dr. Sarah Prichard, M.D. to the Board of Directors
Apr 2, 2014
Kane Biotech Announces Issuance of Common Shares in Payment of Outstanding Interest
Apr 1, 2014
StrixNB(TM) Powder Formulation Approved by Health Canada's LRVHP Program
Mar 26, 2014
StrixNB(TM) Effective Against Cat Bite Wound Infections
Mar 11, 2014
Kane Biotech Receives $397,500 From Warrant Exercise
Feb 4, 2014
DispersinB(R) Topical Spray Approval from Health Canada's LRVHP Program
Jan 7, 2014
Kane Biotech Announces Closing of Private Placement Offering
Dec 18, 2013
Kane Biotech Signs Option Agreement With Global Health Care Company
Dec 17, 2013
Kane Biotech Announces Extension of Warrants and Private Placement Offering
Dec 6, 2013
New StrixNB(TM) Pet Oral Care Approval from Heath Canada's LRVHP Program
Nov 6, 2013
1...
23
24
25
26
27
28
29
30
31
32
...38
